B
Beta Bionics
Automated insulin delivery system that learns and adapts to each user's glucose levels for type 1 diabetes management.
About Beta Bionics
Beta Bionics develops the iLet Bionic Pancreas, an automated insulin delivery system for people with type 1 diabetes. The device integrates with continuous glucose monitors such as Dexcom and FreeStyle Libre to automatically calculate and deliver insulin doses, adapting to each user's needs over time and reducing the manual burden of carb counting and correction doses.
The iLet is a wearable, pocket-sized insulin delivery system cleared for use by people with type 1 diabetes aged six and older. The company also provides a companion app and a user support ecosystem to help patients and caregivers manage therapy.
Beta Bionics manufactures and sells the iLet system in the US, where it is available by prescription. The company is a Massachusetts public benefit corporation and a Certified B Corp, and became publicly traded on Nasdaq in 2025.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Irvine, United States
- Listing
- IPO 2025
- Employees
- 438
- Open positions
- None listed
- Dealroom signal
- 91.3/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Diabetes, Medical Systems, Spinout, Wearable, B Corp, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Apr 2026 | $0 | — | JPMorgan Chase & Co | ↗ |
| POST IPO EQUITYOther financing | Apr 2026 | $0 | — | SG Americas Securities | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth |
|---|---|---|
| 2026 | $133M | +32.1% |
| 2025 | $100M | +54.1% |
| 2024 | $65M | +442.5% |
| 2023 | $12M | +5900% |
| 2022 | $200K | — |
Growth signals
Latest recorded traffic for Beta Bionics is 73K monthly website visits, up 4.3% over the last three months. Beta Bionics's team grew 23.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of Diabetes and Digestive and Kidney Diseases
Series A1 investor entered at this stage
Eventide Asset Management
Series B and later12 investors entered at this stage
Farallon Capital Management
RTW Investments- SCSoleus Capital
Perceptive Advisors
Omega Funds
Sands Capital Management- APArrowMark Partners
- PIPura Vida Investments
Marshall Wace
Wellington Management
JPMorgan Chase & Co- SSSG Americas Securities
Other known investors1 additional known investor
Boston University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Beta Bionics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Beta Bionics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.